# MGR001 / Advair Diskus Local Equivalence Study in Asthma

> **NCT02245672** · PHASE3 · COMPLETED · sponsor: **Mylan Pharma UK Ltd.** · enrollment: 1128 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
- **DRUG:** Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02245672
- **Lead sponsor:** Mylan Pharma UK Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 1128 (ACTUAL)
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02245672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02245672, "MGR001 / Advair Diskus Local Equivalence Study in Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02245672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*